Gómez-Castellano KM, Montes-Luna A, Carballo-Uicab G, Ramírez-Villedas FD, Elizarraras-Rodríguez L, Vázquez-Leiva SK, Rodríguez-Luna SD, González-González E, Pedraza-Escalona M, Holland B, Della-Cristina P, Rivera-Santiago C, Barrera-Saldaña HA, Pérez-Tapia SM, Almagro JC. Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1. mAbs. Dec;17(1):2591461. 2025.

Carballo-Uicab G, Mellado-Sánchez G, González-González E, Salinas-Trujano J, Mendoza-Salazar I, López-Olvera K, Gómez-Castellano KM, Salazar IM, Torres-Flores JM, Chagoya-Cortés HE, Paz-De la Rosa G, Rojas-Martínez O, Lara Puente JH, Peralta-Sánchez GJ, Sarfati-Mizrahi D, Torres-Flores A, Sun W, Krammer F, García-Sastre A, Palese P, López-Macías C, Lozano-Dubernard B, Pérez-Tapia SM, Almagro JC. Addressing SARS-CoV-2 Evolution: Neutralization of Emerging Variants of Concern by the AVX/COVID-12 'Patria' Vaccine Based on HexaPro-S Ancestral Wuhan Spike or Its Updated BA.2.75.2 Version. Frontiers in Immunology. Front. Immunol. 18 May 2025.

Mata-Cruz C, Guerrero-Rodriguez, SL, Gómez-Castellano K, Carballo-Uicab G, Almagro JC, Pérez-Tapia SM, Velasco-Velázquez MA. Discovery and in vitro characterization of a human anti-CD36 scFv. Frontiers in Immunology. 03 February 2025.

Erasmus MF, Spector L, Perea-Schmittle K, Ferrara F, DiNiro R, Pettus C, Rodriguez Carnero LA, Li J, Cisneros A, Fanni A, Pohl TJ, Knight D, Cruz Z, Molina E, Wang W, Tessier P, Richardson C, Turner L, Bedinger D, Sormanni P, Fernandez-Quintero M, Ward A, Raybould M, Evers A, Bachas S, Ruffolo J, Nastri1 H, Ramesh K, Sørenson J, Croasdale-Wood R, Hijano O, Shahsavarian M, Qiu Y, Marcatili P, Vernet E, Akbar R, Friedenson S, Hartman T, Kurella VB, Malhotra A, Kumar S, Kidger P, Almagro JC, Furfine E, Stanton M, Villalba SD, Tomszak F, D’Angelo S, Bradbury ARM. AIntibody: An experimentally-validated in silico antibody discovery design challenge. Nature Biotech. 1-6. 2024.

Pohl MA, Almagro JC. Considerations for Using Phage Display Technology in Therapeutic Antibody Drug Discovery. Advances in Phage Display collection. Eds. Silverman G, Rader C and Sidhu S. Topic Introduction. Cold Spring Harb Protocols.

Maciuba S, Bowden GD, Stratton HJ, Wisniewski K, Schteingart CD, Almagro JC, Valadon P, Lowitz J, Glaser SM, Lee G, Dolatyari M, Navratilova E, Porreca F, Rivière PJM. Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female pain. mAbs. 15: 2254676, 2023.

Godínez-Palma S, González-González E, Ramírez-Villedas F, Garzón-Guzmán C, Vallejo-Castillo L, Carballo-Uicab G, Marcelín-Jiménez Gabriel, Batista D, Pérez-Tapia SM, Almagro JC. Efficacy, pharmacokinetic and toxicity profiles of a broadly SARS-CoV2 neutralizing antibody. Viruses. 15: 1733. 2023.

Guzmán-Bringas OU, Gómez-Castellano K, González-González E, Salinas-Trujano J, Vázquez-Leyva S, Vallejo-Castillo L, Pérez-Tapia SM, Almagro JC. Discovery and optimization of neutralizing SARS-CoV-2 antibodies using ALTHEA Gold Plus Libraries™. Int. J. Mol. Sci. 24: 4609. 2023.

Almagro JC, Mellado-Sánchez G, Pedraza-Escalona M, Pérez-Tapia SM. Evolution of approved anti-SARS-COV-2 therapeutic antibodies. Int. J. Mol. Sci. 23: 9763. 2022.

Pedraza-Escalona M, Guzmán-Bringas O, Arrieta-Oliva I, Gómez-Castellano K, Salinas-Trujano J, Torres-Flores J, Muñoz-Herrera JC, Camacho-Sandoval R, Contreras-Pineda P, Chacón-Salinas R, Pérez-Tapia SM, Almagro JC. Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. BMC Infectious Diseases. 21: 1121, 2021.

Almagro JC, Pedraza M, Arrieta HI, Pérez-Tapia SM. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies. 8: 44, 2019.

Almagro JC, Mascioni A. Developability Assessment of Biologic Drugs. 195-220. In: Developability of Biologics: Safe and Cheaper Medicines via Computation. Ed. Sandeep K. CRC press. 2015.

Almagro JC, Kodangattil S. Novel generation of antibody based therapeutics. 147-170. In: Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Eds Singh M and Salnikova M. Elsevier. 2015.

Almagro JC, Kodangattil S, Li J. Humanized Antibodies. In: Making and Using Antibodies. 395-419. Eds. Howard GC and Matthew R and Kaser MR. 2nd edition. CRC Press. 2013.

Brezski R, Almagro JC. Application of Antibody Engineering in Development of Next Generation Antibody-Based Therapeutics. In: Development of Antibody-Based Therapeutics. 65-93. Eds. Tabrizi MA, Bornstein GG, Klakamp SL. Springer. 2012.

Almagro JC, Strohl WS. Antibody Engineering: Humanization, Affinity Maturation and Selection Methods. 309-334. In: Therapeutic Monoclonal Antibodies: From Bench to Clinic. Ed. Zhiqiang An. John Wiley & Sons, Inc. 2009

Nastri HG, Stewart SM, Almagro JC, Zhou J, Buonpane RA, Wang H, Chen Y, Wang X, Carlsen PN, Li Y, Qi C, Wu L, Yao W, Zhu W, Huang T. Anti-Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy. Assignee: Incyte Corporation, Inc. Priority date: 12/30/2020. US Patent 12,060,433. Issued: 8/13/2024.

Henry R, Samarakoon T, Fishkin N, Zhu P, Pazolli E, Palacino J, Almagro JC. Anti-BCMA antibody-drug conjugates and methods of use. Assignee: Eisai R&D Management Co Ltd. Priority date: 06/04/2021. Publication date: US Patent number 12,043,670. Issued: 7/23/ 2024.

Nastri HG, Stewart SM, Almagro JC, Zhou J, Buonpane RA. Anti-cd73 antibodies and uses thereof. Assignee: Incyte Corporation, Inc. Priority date: 12/30/2020. US Patent 12,018,089. Issued: 6/25/2024.

Gulla SV, Huard C, Buhlmann JE, Almagro JC, Kodangattil SR, Greenberg SA, LaVallie ER, Bennett EM, Mosyak L, Hall JP, Coyle AJ. Interferon beta antibodies and uses thereof. Assignee: Pfizer Inc. Brigham and Women’s Hospital, Inc. Priority date: 12/9/2020. US Patent 11,858,986. Issued: 01/02/2024.

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Neutralizing human anti-CD27 antibodies. Assignee: Janssen Biotech, Inc. Priority Date: 05/19/2020. US Patent: 11,732,050. Issued: 08/22/2023.

Manning PT, Puro R, Almagro JC. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. US Patent: 11,692,035. Issued: 07/04/2023.

Puro R, Hiebsch RR, Capoccia BJ., Andrejeva G, Almagro JC, Pereira DS. Therapeutic SIRP-alpha. antibodies. Assignee: Arch Oncology, Inc. US Patent: 11,202,828. Issued: 12/21/2021.

Almagro JC, DuBell W, Fransson J, Pardinas J, Raghunathan G. Method of treating osteoarthritis with human oncostatin M antibodies. Assignee: Janssen Biotech, Inc. Priority Date: 12/10/2018. US Patent: 10,941,197. Issued: 03/09/2021.

Manning PT, Puro R, Almagro JC, Karr RW. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. Priority Date: 02/08/2019. US Patent: 10,844,124. Issued: 11/24/2020.

Gulla SV, Huard C, Buhlmann, JE, Almagro JC, Kodangattil SR, Coyle AJ. Interferon Beta Antibodies and Uses Thereof. Assignee: PFIZER, INC. Priority Date: 04/29/2016. US Patent: 10,829,553. Issued: 11/10/2020.

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies. JANSSEN BIOTECH, INC. US Patent: 10,689,453. Issued: 06/23/2020.

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies. JANSSEN BIOTECH, INC. US Patent: 10,301,392. Issued: 05/28/2019.

Manning P, Puro R, Almagro JC, Karr RW. Therapeutic CD47 Antibodies. US Patent: 10,239,945. Assignee: Arch Oncology, Inc. Issued: 03/26/2019.

Almagro JC, DuBell W, Fransson J, Pardinas J, Raghunathan G. Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies. JANSSEN BIOTECH, INC. US Patent: 10,179,812. Issued: 01/15/2019.

Almagro JC, Pedraza M, Arrieta HI, Pérez-Tapia SM. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies. 8: 44, 2019.

Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Frontiers in Immunology 8: 1751, 2017.

Finlay WJJ, Almagro JC. Natural and Man-made V-region repertoires for Antibody Discovery. Frontiers in Immunology. 3: 1-18, 2012.

Gilliland GL, Luo J, Vafa O and Almagro JC. Leveraging SBDD in protein therapeutic development: antibody engineering. Methods in Molecular Biology. 841: 321-349, 2012.

Almagro JC, Fransson J. Humanization of antibodies. Frontier in Biosciences. 13:1619-1633, 2008.